Official kick-off meeting of the „antiviral therapies“ research program funded by the Baden-Württemberg Stiftung – with the project HuCytoViMab, a collaboration between the group of Prof. Hartmut Hengel (Uni Freiburg) and Roland Kontermann (IZI) to develop therapeutic antibodies against HCMV